Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 43.4% in the 2nd quarter, Holdings Channel reports. The firm owned 394,259 shares of the medical research company’s stock after selling 301,716 shares during the quarter. William Blair Investment Management LLC’s holdings in Charles River Laboratories International were worth $82,893,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in CRL. Moneta Group Investment Advisors LLC acquired a new stake in shares of Charles River Laboratories International in the 4th quarter worth $298,877,000. Price T Rowe Associates Inc. MD increased its stake in shares of Charles River Laboratories International by 35.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock worth $505,821,000 after acquiring an additional 653,790 shares during the last quarter. Norges Bank acquired a new stake in shares of Charles River Laboratories International in the 4th quarter worth $97,675,000. Southpoint Capital Advisors LP acquired a new stake in shares of Charles River Laboratories International in the 1st quarter worth $80,728,000. Finally, Clearbridge Investments LLC increased its stake in shares of Charles River Laboratories International by 28.2% in the 1st quarter. Clearbridge Investments LLC now owns 1,368,943 shares of the medical research company’s stock worth $388,739,000 after acquiring an additional 301,159 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on CRL shares. Guggenheim cut their target price on Charles River Laboratories International from $255.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, September 22nd. StockNews.com assumed coverage on Charles River Laboratories International in a research report on Thursday, October 5th. They issued a “hold” rating for the company. TD Cowen dropped their target price on Charles River Laboratories International from $212.00 to $209.00 and set a “market perform” rating for the company in a research report on Monday, September 25th. Bank of America decreased their price objective on Charles River Laboratories International from $245.00 to $230.00 in a research note on Friday, September 22nd. Finally, Wells Fargo & Company decreased their price objective on Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating for the company in a research note on Friday, September 22nd. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus price target of $232.54.

Charles River Laboratories International Price Performance

CRL stock opened at $192.72 on Tuesday. The business has a 50 day moving average price of $188.36 and a 200 day moving average price of $198.29. The stock has a market cap of $9.88 billion, a price-to-earnings ratio of 20.62, a PEG ratio of 2.00 and a beta of 1.35. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $262.00. The company has a quick ratio of 1.16, a current ratio of 1.45 and a debt-to-equity ratio of 0.76.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 8th. The medical research company reported $2.72 earnings per share for the quarter, topping the consensus estimate of $2.35 by $0.37. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1 billion. Charles River Laboratories International had a return on equity of 18.15% and a net margin of 11.27%. The firm’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.63 earnings per share. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO James C. Foster acquired 5,620 shares of Charles River Laboratories International stock in a transaction on Tuesday, November 14th. The stock was bought at an average price of $178.05 per share, for a total transaction of $1,000,641.00. Following the completion of the purchase, the chief executive officer now owns 202,643 shares in the company, valued at $36,080,586.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Richard F. Wallman acquired 1,000 shares of Charles River Laboratories International stock in a transaction on Thursday, August 24th. The stock was bought at an average price of $198.79 per share, for a total transaction of $198,790.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $198,790. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James C. Foster acquired 5,620 shares of Charles River Laboratories International stock in a transaction on Tuesday, November 14th. The stock was purchased at an average price of $178.05 per share, with a total value of $1,000,641.00. Following the purchase, the chief executive officer now owns 202,643 shares of the company’s stock, valued at approximately $36,080,586.15. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).